Thienopyridine antiplatelet agents: focus on prasugrel

Area of Science:

• Cardiology
• Pharmacology
• Geriatrics

Background:

• Thienopyridine antiplatelet agents like clopidogrel have limitations including variability and drug interactions.
• Prasugrel represents a newer generation with distinct pharmacokinetic and pharmacodynamic properties.

Purpose of the Study:

• To evaluate the role of prasugrel in managing acute coronary syndrome (ACS) in elderly patients.
• To compare prasugrel's efficacy and safety profile against existing antiplatelet therapies.

Main Methods:

• Systematic literature review of PubMed and International Pharmaceutical Abstracts (1966-2009).
• Inclusion of human studies assessing prasugrel's pharmacokinetics, pharmacodynamics, and clinical efficacy.

Main Results:

• Prasugrel provides more potent platelet inhibition and better cardiovascular outcomes than clopidogrel.
• An increased risk of bleeding is associated with prasugrel, particularly in specific populations.
• Contraindications include age >75, recent TIA/stroke, low body weight (<60kg), and concurrent bleeding risk factors.

Conclusions:

• Prasugrel demonstrates consistent platelet inhibition and superior cardiovascular outcomes versus clopidogrel, without need for renal/hepatic dose adjustments.
• It shows potential for ACS patients with clopidogrel resistance or high cardiovascular risk, though further trials are needed.
• Geriatric patients exhibit a higher bleeding risk; precise patient selection for prasugrel requires additional research.